Seven sentenced after MHRA investigation uncovers £1.8m illegal medicines and steroids network

An MHRA-led investigation has exposed a £1.8 million illegal medicines and steroids network, leading to seven men being sentenced

Seven men have been sentenced after an investigation by the Medicines and Healthcare products Regulatory Agency’s (MHRA) Criminal Enforcement Unit into a large-scale criminal network supplying illegal steroids and prescription-only medicines. The group received combined sentences totalling more than 21 years’ imprisonment. 

The investigation began after UK Anti-Doping (UKAD) identified website linked to the Bolton area that were suspected of selling performance-enhancing steroids and other illegal medicines. 

MHRA investigators traced the activity to a flat above commercial premises on St Helens Road, which was being used to store, package, and distribute the drugs. 

During enforcement action, officers seized more than 130,000 doses of steroids and unauthorised medicines that were being sold by mail order. These included products such as tamoxifen, finasteride and modafinil, highlighting the scale and complexity of the illegal supply network. Further searches across Bolton led to a number of arrests. 

Following a detailed investigation, several individuals were charged with offences including conspiracy to supply controlled drugs, supplying unauthorised medicines, and money laundering to the value of over £1.8 million.  

Tim Duffield, MHRA Head of Intelligence said: ““This was a well-organised operation that put people at real risk. Medicines bought outside regulated channels can be unsafe, ineffective or fake. 

“Our investigators worked hard to break up this criminal network and bring those responsible to justice. These convictions are just part of the MHRA’s ongoing work to tackle the illegal trade in medicines and protect public health.” 

Mario Theophanous, UKAD’s Head of Intelligence and Investigations, said: “Disrupting the supply of illegal performance-enhancing drugs is central to protecting sport.

“Our intelligence officers work in partnership with regulators and law enforcement, to identify and dismantle the criminal networks that make these substances available. That collaboration is a vital part of how we keep prohibited substances out of sport, and away from elite athletes and young people.” 

Zaheer Oomer, who is unemployed, pleaded guilty at an early stage to all charges, including money laundering offences to a value of £99,893.  

Rizwan Atcha, a health and safety advisor, Imtiaz Atcha, a former bank manager, and Matthew Williams, a care worker, also pleaded guilty at the start of the trial in June 2025. Each admitted money laundering offences to the value of £772,112, £117,733 and £221,349 respectively.

Abdul Khan, a scrap metal dealer, Saddym Shahid, a mechanic, and Rajendra Patel, a scrap metal worker, pleaded not guilty and stood trial at Bolton Crown Court. They faced charges of money laundering involving £139,967, $248,750 and £229,061 respectively. Following consideration of extensive evidence, the jury found all three men guilty on 7 July 2025. 

A Proceeds of Crime Act confiscation investigation is ongoing. 

The MHRA reminds the public to only obtain medicines from trusted and regulated sources, such as registered pharmacies.

Anyone who suspects they have been sold illegal or unsafe medicines, or is experiencing side effects, should seek medical advice and report any concerns to the MHRA’s Yellow Card scheme.  

Convictions 

  • Abdul Khan and Saddaym Shahid – Conspiracy to supply class C drugs 4 years imprisonment. Conspiracy to supply unauthorised medicinal products 18 months imprisonment concurrent. Money laundering 3 years imprisonment consecutive. Total 7 years imprisonment. 
  • Mohammed Oomer – Conspiracy to supply class C drugs 35 months imprisonment. Conspiracy to supply unauthorised medicinal products 18 months imprisonment concurrent. Money laundering 20 months imprisonment consecutive. Total 4 years 7 months. 
  • Rizwan Atcha – 4 counts of money laundering. 37 months imprisonment concurrent on each count. Total 3 years and 1 month imprisonment. 
  • Imtiaz Atcha – 4 counts of money laundering. 18 months imprisonment suspended for 2 years. Electronically monitored curfew from 9pm to 7pm for four months. To do 250 hours of unpaid work.  
  • Rajendra Patel – 2 counts of money laundering. 24 months imprisonment suspended for 2 years. Electronically monitored curfew from 9pm to 7pm for four months. To do 250 hours of unpaid work. 
  • Matthew Williams – 4 counts of money laundering. 24 months imprisonment suspended for 2 years. Electronically monitored curfew from 9pm to 7pm for four months. To do 250 hours of unpaid work. 

MHRA: NO EVIDENCE that taking paracetamol during pregnancy causes autism in children

There is no evidence that taking #paracetamol during pregnancy causes autism in children.

Always follow NHS guidance and report any suspected side effects via the Yellow Card scheme https://bit.ly/2A6B165

Dr Alison Cave, Chief Safety Officer at the MHRA, said:Patient safety is our top priority. There is no evidence that taking paracetamol during pregnancy causes autism in children.   

“Paracetamol remains the recommended pain relief option for pregnant women when used as directed. Pregnant women should continue to follow existing NHS guidance and speak to their healthcare professional if they have questions about any medication during pregnancy.

“Untreated pain and fever can pose risks to the unborn baby, so it is important to manage these symptoms with the recommended treatment. 

https://twitter.com/i/status/1970506529125064995

“Our advice on medicines in pregnancy is based on rigorous assessment of the best available scientific evidence. 

“Any new evidence that could affect our recommendations would be carefully evaluated by our independent scientific experts. 

“We continuously monitor the safety of all medicines, including those used during pregnancy, through robust monitoring and surveillance. We encourage anyone to report any suspected side effects to us via the Yellow Card scheme.”

Paracetamol is recommended as the first-choice painkiller for pregnant women, used at the lowest dose and for the shortest duration.

If pain does not resolve, then patients are advised to seek advice from their healthcare professional.

See NHS Guidance – Pregnancy, breastfeeding and fertility while taking paracetamol for adults 

Scottish Autism is aware that pronouncements regarding autism from the US Government will be a source of anxiety and worry for many in our community.

We are clear that public policy should be focused on recognising and accommodating the needs and rights of autistic people rather than stigmatising neurodivergence as something to be ‘treated’ or prevented. Spreading misinformation about the identified reasons why some people are born autistic does nothing to further this aim.

Scottish Autism’s focus is on finding better ways to support autistic people and their families. Our research, campaigning and service provision reflect this priority and always will.

Our Advice Line is open 10am-4pm Monday, Tuesday, Thursday & Friday and our Community Advisors can help you to identify what support may exist in your area.

You can call the Advice Line on 01259 222022, email advice@scottishautism.org or LiveChat with us via our website.

Women on “skinny jabs” must use effective contraception, MHRA urges

Anyone who suspects that they’ve had an adverse reaction to their weight loss or diabetes medicine or suspects it is not a genuine product, should report it to the MHRA. 

Women taking popular medicines for weight loss and diabetes, sometimes referred to as “skinny jabs”, are being reminded to use effective contraception while taking these medicines and, in some cases, for up to two months between stopping the medicine and trying to get pregnant.  

These medicines must not be taken during pregnancy, while trying to get pregnant, or during breastfeeding. Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible. This is because there is not enough safety data to know whether taking the medicine could cause harm to the baby. 

Effective contraception includes oral (the pill) and non-oral (the implant, coil or condoms) forms of contraception. However, Mounjaro may reduce the effectiveness of oral contraceptives in those who are overweight. Therefore, those taking Mounjaro who are overweight and are using an oral form of contraception are advised to also use a non-oral form of contraception. This only applies to those taking Mounjaro and is especially important for the four weeks after starting Mounjaro and after any dose increase. 
 
This advice, which is already in the patient leaflets that come with the medicine, is just one of the reminders in the latest guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) on the safe use of “GLP-1 medicines” known by the brand names Ozempic, Mounjaro, Wegovy, Saxenda and Victoza.  

The full advice can be found on the regulator’s website. It comes after concerns from the UK regulator that some people are not using these medicines for weight loss and diabetes safely.  

Dr Alison Cave, MHRA Chief Safety Officer said:Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments. They are not a quick fix to lose weight and have not been assessed to be safe when used in this way. 

“Our guidance offers patients a “one stop shop” for our up-to-date advice on how to use these powerful medicines safely.  

“This guidance should not be used as a substitute to reading the patient information leaflet or having a conversation with a healthcare professional as part of the prescribing process. ” 

Alongside advice on contraceptive use, the MHRA reminds patients that these medicines should not be bought from unregulated sellers such as beauty salons or via social media, or taken without a prior consultation with a healthcare professional.

Not only does this expose people wanting to lose weight to serious health risks, it is also against the law to sell these medicines in this way. 

The only way to guarantee receiving a genuine GLP-1 medicine is to obtain it from a legitimate pharmacy.  

The guidance also reminds patients of the symptoms to look out for in the event of acute pancreatitis which, although uncommon, can be serious.

The main symptom of this is severe pain in the stomach that radiates to the back and doesn’t go away. Anyone who experiences this should seek immediate medical help. 

Summary of advice to patients

  • You should only take GLP-1 medicines if they have been prescribed to you by a healthcare professional.   
  • Always have a conversation with your prescriber about the benefits and risks of GLP-1 medicines before you start taking them.   
  • Do not take GLP-1 medicines if you are pregnant, trying to get pregnant or breastfeeding. If you get pregnant while using them, you speak to a healthcare professional and stop them as soon as possible.
  • If you are prescribed Mounjaro (tirzepatide), use a barrier form of contraception and do not rely on oral contraception.   
  • Understand the potential side effects and have a conversation with a healthcare professional if you are concerned.   
  • Tell your doctor you take a GLP-1 medicine if you are about to have surgery.   
  • Report any adverse reactions to the Yellow Card scheme.   
  • After taking the recommended four doses in each syringe, any medicine left in the syringe should not be extracted and the syringe should be disposed of in the bin.  
  • Use of these medicines is not a quick fix to lose weight and the MHRA has not assessed the safety and effectiveness of these medicines when used by people who do not meet the medical requirements.   

Anyone who suspects that they’ve had an adverse reaction to a GLP-1 medicine,  or suspects it is not a genuine product, should report it to the MHRA Yellow Card scheme.   

Safety withdrawal of pholcodine-containing cough and cold medicines

Following a comprehensive scientific safety review of the latest available data on the safety of pholcodine, together with advice from the independent Commission on Human Medicines, it has been concluded that the potential risks outweigh the benefits for these products.

The Medicines and Healthcare products Regulatory Agency (MHRA) keeps the safety of medicines under review and acts where necessary to protect patients and the public.

Following a comprehensive scientific safety review of the latest available data on the safety of pholcodine, together with advice from the independent Commission on Human Medicines, it has been concluded that the potential risks outweigh the benefits for these products.

There is already a known link between pholcodine and an increased risk of the very rare event of a severe allergic reaction (anaphylaxis) to muscle relaxants (neuromuscular blocking agents) that are used during general anaesthesia in surgery. In September 2022 the findings of a new study further strengthened the evidence of this link, but the overall risk is very small.

The MHRA advises that pholcodine-containing cough and cold medicines are being removed from the UK market as a precautionary measure.

Dr Alison Cave, MHRA Chief Safety Officer said: “Safety is our top priority, and we keep the safety of medicines under continual review.

“Following a thorough scientific safety review of all the available evidence on pholcodine, together with advice from the independent Commission on Human Medicines, it has been recommended, as a precautionary measure, that these products should no longer be used.

“If you are taking a cough or cold medicine, check the packaging, label or patient information leaflet to see if pholcodine is a listed ingredient. If it is, and you have any questions, you can talk to your pharmacist who will suggest an alternative medicine.

“If you have an operation scheduled using general anaesthesia, tell your anaesthetist if you think you have used pholcodine, particularly in the past 12 months. The anaesthetist will be well placed to take this into account. Anaesthetists are highly trained in managing anaphylaxis.

“If you want more information or advice, please speak to your pharmacist.”

See the MHRA Drug Safety Update